GMP Cytokines Optimization for Closed System T Cell Therapy Manufacturing

Overview
In this case study, a company focused on autologous T cell therapies targeting solid tumor cancers was progressing into clinical trials and needed to transition from research-grade to GMP-grade cytokines. Concurrently they wanted to improve
their methods of cytokine supplementation to reduce cytokine waste, improve dose accuracy across lots, and
reduce process risk by defining methods for closed-system cytokine addition. ScaleReady detailed a plan to help them achieve these goals.
What this paper found
A company developing autologous T cell therapies for solid tumours completed the switch from research-grade to GMP-grade cytokines after generating data showing comparable bioactivity and consistent lot-to-lot performance across three lots of each GMP cytokine. ScaleReady supplied certificates of analysis, stability data and bioactivity documentation for specification comparison, and the company confirmed that the GMP and research-grade proteins use the same clone and manufacturing process. On waste, 2 of the 3 GMP cytokines were already sold off-the-shelf in smaller vials meeting the minimum activity per vial the process needed, and custom activity-per-vial filling is being pursued for the third. Prototype closed-system cytokines in bags were provided for evaluation of ease-of-use and performance equivalency.
Study details
- Cell type(s)
- T-Cells
- Application area
- Solid tumor
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.